In vitro study | LDN193189 can effectively inhibit the activation of Smad1, Smad5 and Smad8 mediated by BMP4, The IC50 is 5 nM, and can also effectively inhibit the transcriptional activity of BMP I-type receptor ALK2 and alk3, IC50 is 5nM and 30 nM respectively. In addition, a recent study by LDN193189 on persistently activated ALK2 showed that in human arterial endothelial cells, LDN-193189 blocked the production of oxidative free radicals induced by oxidized LDL. |
In vivo study | Carrying Ad. LDN-193189 (3 mg/kg, I. P.) induced weak left tibia and fibula calcification, visible on day 13, in conditioned caALK2 transgenic mice at 7 postnatal days, the lesion was blocked on day 15 without causing weight loss or growth retardation, spontaneous fractures, decreased bone density, or behavioral abnormalities. LDN193189 forms curved zebrafish embryos by inhibiting bone morphogenetic protein (BMP)6-induced signaling, while having no effect on vascular development. In mice with PCa-118b tumors, LDN-193189 treatment slowed tumor growth and decreased bone formation in the tumors. In LDLR-/-mice, LDN-193189 inhibits the development of atheroma. In addition, LDN-193189 has an inhibitory effect on vascular inflammation, Osteogenic Activity and calcification. |